文献速递头痛与眩晕

接受单克隆抗CGRP(受体)抗体治疗的偏头痛患者的血压:一项前瞻性随访研究

Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies: A Prospective Follow-up Study.
PubMed 文献 · Neurology · 2022-10-04

该前瞻性随访研究纳入2019年1月至2021年1月在Leiden头痛中心接受erenumab或fremanezumab治疗的偏头痛患者,随访12个月、每3个月测量血压。结果显示,抗CGRP(受体)抗体治疗后平均收缩压和舒张压均升高,最大估计收缩压升高5.2 mm Hg(95% CI 3.1-7.5),舒张压升高3.5 mm Hg(95% CI 2.0-4.9),多数患者血压仍在正常范围内,但部分患者需加用降压药。

要点

  • 抗CGRP(受体)抗体治疗后,T1-T4各时间点收缩压和舒张压均较基线升高(p < 0.001)。
  • 平均收缩压最大估计升高5.2 mm Hg(95% CI 3.1-7.5),舒张压最大估计升高3.5 mm Hg(95% CI 2.0-4.9)。
  • erenumab组(n = 109)各时间点收缩压和舒张压均较基线升高(均p < 0.001);fremanezumab组(n = 87)仅T1(p = 0.006)和T2(p = 0.004)收缩压较基线升高。

核心结论

  • 开始抗CGRP(受体)抗体治疗后,平均收缩压和舒张压升高;多数患者血压仍在正常范围内,但部分患者需加用降压治疗。
  • 作者认为,医生应意识到偏头痛患者在接受抗CGRP(受体)抗体治疗时可能有发生高血压的风险,并应将此写入(各)国家治疗指南。

研究设计与样本

  • 前瞻性随访研究,纳入2019年1月至2021年1月在Leiden头痛中心接受erenumab和fremanezumab治疗的偏头痛患者。
  • 从基线(T0)至随访12个月收集血压测量值,每3个月一个间隔(T1-T4)。
  • 采用混合线性模型,以时间为固定效应、患者为随机效应。

主要发现

  • 与T0相比,T1-T4所有时间点收缩压和舒张压均升高(p < 0.001)。
  • 平均收缩压最大估计升高5.2 mm Hg(95% CI 3.1-7.5),平均舒张压最大估计升高3.5 mm Hg(95% CI 2.0-4.9)。
  • erenumab组(n = 109)所有时间点收缩压和舒张压均较T0升高(均p < 0.001)。
  • fremanezumab组(n = 87)T1(p = 0.006)和T2(p = 0.004)收缩压较T0升高,舒张压未升高。
  • 4例(3.7%)基线血压正常的患者在开始erenumab后需接受降压治疗。

关键数值与推荐

  • 该研究提供III级证据表明,抗CGRP(受体)抗体用于治疗偏头痛患者时升高血压。

临床怎么用

  • 作者认为,医生应意识到偏头痛患者在接受抗CGRP(受体)抗体治疗时可能有发生高血压的风险。
  • 作者认为,这一风险应写入(各)国家治疗指南。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Anti-calcitonin gene-related peptide (CGRP) (receptor) antibodies are approved as preventive treatment for migraine. Recent concerns have been raised after a retrospective analysis of postmarketing case reports of elevated blood pressure (BP) associated with erenumab. In this prospective follow-up study, we aimed to assess the safety regarding BP in a real-world setting. METHODS: All people with migraine who were treated with erenumab and fremanezumab at the Leiden Headache Center between January 2019 and January 2021 were included. BP measurements were collected from baseline (T0) until 12 months of follow-up, with a 3-month interval (T1-T4). Mixed linear models were fitted with time as a fixed effect and the patient as a random effect. RESULTS: Both systolic and diastolic BP were increased at all time points T1-T4 compared with T0 (p < 0.001). The maximum estimated increase in the mean systolic BP was 5.2 mm Hg (95% CI 3.1-7.5). The maximum estimated increase in the mean diastolic BP was 3.5 mm Hg (95% CI 2.0-4.9). In the erenumab group (n = 109), both systolic and diastolic BP were increased at all time points compared with T0 (all p < 0.001). For fremanezumab (n = 87), systolic but not diastolic BP was increased compared with T0 at T1 (p = 0.006) and T2 (p = 0.004). Four patients (3.7%) with normal BP at T0 required antihypertensive treatment after erenumab was started. DISCUSSION: The mean systolic and diastolic BP increased after anti-CGRP (receptor) antibodies were started. The majority of patients remained within the normal BP limits, but some patients required antihypertensive treatment. Physicians should be aware that people with migraine may be at risk of developing hypertension when treated with anti-CGRP (receptor) antibodies, and this should be added to (inter)national treatment guidelines. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that anti-CGRP (receptor) antibodies increase BP when used to treat patients with migraine.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. de Vries Lentsch S, van der Arend BWH, Maassen VanDenBrink A, et al. Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies: A Prospective Follow-up Study. Neurology. 2022. PMID: 36195452. doi:10.1212/WNL.0000000000201008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。